21 Dec 2025 by admin in UncategorizedComments Windward Bio Expands Immunology Pipeline With WIN027, a Long-Acting, Clinical-Stage Bispecific Targeting TSLP and IL-13
15 Dec 2025 by admin in UncategorizedComments Zenas BioPharma’s Partner, InoCare Pharma, Anounces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
